Adcendo Secures $75 Million Series C to Advance First-in-Class ADC Pipeline for High Unmet Need Cancers
核心洞察
Adcendo ApS completed an oversubscribed $75 million Series C financing round led by Jeito Capital (搜索) to advance three first- and best-in-class antibody-drug conjugates through upcoming clinical milestones.
The funding will support advancement of ADCE-T02 targeting Tissue Factor (搜索) in multiple solid tumors, ADCE-D01 targeting uPARAP (搜索) in soft tissue sarcoma, and ADCE-B05 in squamous cell carcinomas.
The company's experienced leadership team has a proven track record of advancing multiple ADCs to approval, positioning them to address cancers with high unmet medical needs.
Copenhagen-based clinical-stage biotechnology company Adcendo ApS has successfully closed an oversubscribed $75 million Series C financing round to advance its pipeline of first- and best-in-class antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs. The financing was led by Jeito Capital (搜索), with participation from new investors Vida Ventures (搜索), BPI France (搜索), and EIFO (搜索), as well as all existing investors.
Advancing Three Differentiated ADC Programs
The proceeds will support Adcendo through multiple upcoming clinical milestones across its three-drug pipeline. The company is advancing ADCE-T02, a Tissue Factor (搜索) ADC currently in the Phase I Tiffany-01 Cohort expansion study across multiple high unmet need tumor indications. Tissue Factor is overexpressed in a broad range of solid tumors, including head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, colorectal cancer and non-small cell lung cancer.
The funding will also advance ADCE-D01, which targets uPARAP (搜索) and is being evaluated in the ADCElerate1 dose escalation and expansion study in soft tissue sarcoma and other cancers of mesenchymal origin. Additionally, the company is progressing ADCE-B05, an ADC with an undisclosed target currently being evaluated pre-clinically in squamous cell solid tumors, through dose escalation studies.
Addressing Critical Unmet Medical Needs
"This successful financing round, led by a distinguished group of life science investors, empowers us to continue advancing our pipeline of breakthrough ADCs for the treatment of underserved cancers," said Michael Pehl, Chief Executive Officer of Adcendo. "We are thrilled to see continued momentum of our first and best-in-class ADCs in clinic, and with the backing of this fundraising we will continue to progress ADCE-T02, ADCE-D01 and ADCE-B05 through upcoming data readouts."
The company's approach addresses ongoing challenges in ADC technology, as numerous types of cancers still have patients with high unmet medical needs, with systemic toxicities remaining a key limitation of available treatments. Adcendo integrates novel targets, optimized linker-payload combinations, and a rationally designed development strategy to drive next-generation cancer therapies.
Strong Investor Confidence and Leadership
Ksenija Pavletic, General Partner & Chief Commercial Officer at Jeito Capital (搜索), commented: "Adcendo stands out in the ADC field as having a noteworthy combination of bold innovation and strong clinical development strategy and execution. With a seasoned team of drug developers and biopharma leaders advancing their differentiated pipeline, we are excited to see the Company's progress toward their mission of delivering next-generation cancer therapies to patients who need them most."
Dr Rafaèle Tordjman, MD, PhD, Founder & CEO of Jeito Capital (搜索), added: "Oncology remains one of the most critical areas of unmet medical need, and ADCs represent a transformative approach to delivering targeted therapies with improved efficacy and tolerability. Adcendo's experienced leadership team, with a proven track record in ADC development, is advancing a truly differentiated pipeline with the potential to redefine treatment outcomes for patients with difficult-to-treat cancers."
As part of the financing, Adcendo will add Ksenija Pavletic from Jeito Capital (搜索) and Rajul Jain from Vida Ventures (搜索) to its Board of Directors. The company is led by a team of experienced biopharma executives with a track record of advancing multiple ADCs to approval.
Strategic Investment in European Biotech Innovation
Jeito Capital (搜索), which led the financing round, manages €1.6 billion in assets and focuses on financing ground-breaking medical innovation with a patient benefit-driven approach. The investment firm has built a strong oncology portfolio, including recent investments in Callio Therapeutics, Alentis Therapeutics, CDR-Life, CatalYm, and Neogene Therapeutics, which was acquired by AstraZeneca in 2023.
The successful financing positions Adcendo to continue its mission of delivering next-generation cancer therapies to patients with difficult-to-treat cancers, leveraging its differentiated ADC platform and experienced development team.